Antithrombotic Treatment After Coronary Intervention: Agreement and Controversy

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Pharmacology

Background:

• Percutaneous coronary intervention (PCI) for ischemic heart disease has advanced significantly with new devices, techniques, drugs, and strategies.
• Combination therapy with antiplatelet agents is crucial for preventing stent thrombosis post-PCI.
• The optimal duration of dual antiplatelet therapy (DAPT) or combined antiplatelet/anticoagulant regimens is a subject of ongoing research and clinical debate.

Purpose of the Study:

• To review current evidence and guidelines on antiplatelet and anticoagulant therapy use following PCI.
• To focus on trials and recommendations concerning variable durations of combination antithrombotic regimens.
• To discuss alternative antithrombotic strategies and decision-making factors in clinical practice.

Main Methods:

• Review of recent clinical trials and current international guidelines.
• Analysis of studies evaluating prolonged versus shortened durations of combination antithrombotic therapy.
• Synthesis of evidence considering patient profiles and procedural characteristics influencing treatment decisions.

Main Results:

• Evidence suggests that modifying the duration of combination therapy (prolonging or shortening) impacts clinical outcomes differently across various patient populations and procedural complexities.
• Patient-specific risk factors (e.g., bleeding risk, thrombotic risk) and procedural factors (e.g., stent type, complexity) are key determinants for tailoring antithrombotic therapy.
• Ongoing research continues to refine recommendations for optimal treatment duration and alternative strategies.

Conclusions:

• Personalized antithrombotic strategies, balancing efficacy and safety, are essential after PCI.
• Clinical decisions regarding the duration of antiplatelet/anticoagulant therapy should be individualized based on comprehensive patient and procedural assessments.
• Further research is needed to optimize antithrombotic regimens for diverse patient groups undergoing PCI.